Ornipressin (omithine-8-vasopressin, POR-8) is the most commonly used vasopressin analogue in Germany, Switzerland, New Zealand and Australia. While it has minimal antidiuretic activity whilst maintaining equipotent vasoconstrictor activity as the natural hormone, vasoprssin.
CAT No: 10-101-40
CAS No:3397-23-7
Synonyms/Alias:ORNIPRESSIN;Ornipressine;Ornipresina;Orpressin;3397-23-7;POR 8;Ornipressin [INN];Ornipressina;Ornipressinum;Ornithine Vasopressin;8-Ornithinevasopressin;8-L-Ornithinevasopressin;Orn(8)-vasopressin;POR 8 Sandoz;(Orn8) Vasopressin;POR-8;Ornipressina [DCIT];Ornipresina [INN-Spanish];Ornipressine [INN-French];Ornipressinum [INN-Latin];UNII-1KTH6N080W;Vasopressin, 8-L-ornithine-;1KTH6N080W;ORNIPRESSIN [MI];EINECS 222-253-8;ORNIPRESSIN [MART.];ORNIPRESSIN [WHO-DD];(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;CHEMBL1819440;Ornipressin (INN);Ornipressin Diacetate Salt;Ornipresina (INN-Spanish);Ornipressine (INN-French);Ornipressinum (INN-Latin);ORNIPRESSIN (MART.);(2S)-N-[(2S)-5-Amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13R,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULFIDE);CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULPHIDE);POR 8 Sandoz (TN);(2S)-N-((2S)-5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-((4-hydroxyphenyl)methyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide;Vasopressin, Ornithine;Ornithine 8 Vasopressin;Ornithine-8-Vasopressin;SCHEMBL296322;H01BA05;CHEBI:136020;MUNMIGOEDGHVLE-LGYYRGKSSA-N;HY-P0083;BDBM50350865;AKOS030529555;CS-5839;DB13464;NCGC00509864-02;DA-56485;NS00049980;Q3038432;(S)-N-((S)-5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide;222-253-8;
We sought to evaluate the efficacy and side effect profile of a small dose of ornipressin, a vasopressin agonist specific for the V1 receptor, administered to reverse the hypotension associated with combined general/epidural anesthesia. A total of 60 patients undergoing intestinal surgery were studied. After the induction of anesthesia, 7-8 mL of bupivacaine 0.5% with 2 microg/kg clonidine and 0.05 microg/kg sufentanil after an infusion of 5 mL of bupivacaine 0.06% with 0.5 microg x kg(-1) x h(-1) clonidine and 0.1 microg/h of sufentanil were administered by an epidural catheter placed at T7-8 vertebral interspace. When 20% reduction of baseline arterial blood pressure developed, patients were randomly assigned to receive, in a double-blinded design, dopamine started at 2 microg x kg(-1) x min(-1), norepinephrine started at 0.04 microg x kg(-1) x min(-1), or ornipressin started at 1 IU/h. Fifteen patients presenting without hypotension were used as control subjects. Beside routine monitoring, S-T segment analysis, arterial lactacidemia, and gastric tonometry were performed. Ornipressin restored arterial blood pressure after 8 +/- 2 vs 7 +/- 3 min in the norepinephrine group and 11 +/- 3 min in the dopamine group (P < 0.05). This effect was achieved with 2 IU/h of ornipressin in most of the patients (11 of 15). Ornipressin did not induce any modification of the S-T segment; however, it significantly increased intracellular gastric PCO(2) (P < 0.05), indicating splanchnic vasoconstriction.
De Kock, M., Laterre, P. F., Andruetto, P., Vanderessen, L., Dekrom, S., Vanderick, B., & Lavand'homme, P. (2000). Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesthesia & Analgesia, 90(6), 1301-1307.
3. Myotropic activity of allatostatins in tenebrionid beetles
5. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More